Importance Approximately 125 million people worldwide have psoriasis. Patients with
psoriasis experience substantial morbidity and increased rates of inflammatory arthritis, …

… Armstrong has received consulting fees, speaking fees, and/or honoraria from AbbVie,
Amgen, Janssen, Merck, Lilly, Novartis, and Pfizer (less than $10,000 each). Dr. Boehncke has …

Background Psoriasis is a chronic inflammatory disorder associated with significant morbidity
and mortality. Up-to-date prevalence data on psoriasis provide the foundation for informing …

Background Early clinical studies suggested that the anti–interleukin-17 receptor A monoclonal
antibody brodalumab has efficacy in the treatment of psoriasis. Methods In two phase 3 …

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Background Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal
antibody, was efficacious in psoriasis. Objective We sought to assess efficacy and safety of …

Objective: Psoriasis is an inflammatory skin disease affecting 2–4% of the world population.
The objective of this study was to perform a systematic review and meta-analysis …

BACKGROUND: Increasing population-based studies have suggested a relationship
between psoriasis and metabolic syndrome. OBJECTIVE: The objective of this study was to …

Background Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with
few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor …

Methods: Comparisons of death-related variables during the 3 eras were performed. Results:
The number of deaths declined over the study period, with 987 deaths in the pre-HAART …